Search This Blog

Monday, July 29, 2019

Insurers see roadblocks to nonmedical Medicare Advantage benefits

New regulatory flexibility letting Medicare Advantage plans sell supplemental benefits has opened up a new world of services, from transportation to nutrition, for tens of millions of beneficiaries. But implementation challenges, uncertain return on investment and a lack of clarity on what benefits are allowed may be giving payers, especially the smaller ones, pause on offering the options, experts say.
CMS expanded supplemental benefits in the popular privately-run Medicare plans in an April final rule. Now, Medicare Advantage plans can offer a host of non-traditional benefits, such as at-home grocery delivery, non-emergency medical transportation to doctor appointments or home modifications like installing air conditioning for beneficiaries with asthma and home renovations for fall-prone elderly.
And the department wants to go further than the MA supplemental benefits introduced in April, HHS Secretary Alex Azar said this week at a Better Medicare Alliance annual conference. Because MA plans have budgetary restrictions and a higher risk appetite, the government is comfortable granting them more leeway if it lowers costs and boosts health outcomes.
“We want to open up more opportunities for MA plans and entities they work with, including creative value-based insurance design arrangements, moving care to the home and community and new ways for MA plans to improve a patients’ health over the long term,” Azar said Tuesday.
A number of payers have increased their MA offerings recently to till the fertile ground set up by CMS, including startups Bright Health and Oscaralong with heftier players like Centene and UnitedHealthcare.
Currently, MA plans enroll more than one-third of all Medicare beneficiaries, and enrollment is rising steadily every year. At least 40% of those plans offered non-medical benefits in the current plan year at no additional cost to beneficiaries, according to consultancy Avalere.
But further flexibility could present a problem for payers already struggling to assimilate to the increased flexibility and the administrative burden it entails.

Not enough time, money or guidance

Though it approved of the flexible benefit options, payer lobby America’s Health Insurance Plans was concerned in April about the regulatory changes coming just two months before the submission deadline for plan offerings for the 2020 plan year.
That’s because shaping a new benefit can take two to three years, Robert Saunders, research director at the Duke-Margolis Center for Health Policy, told Healthcare Dive. Plans have to work with their actuaries to price what a potential benefit is worth and then incorporate that into their bid.
“Just because you have policy flexibility doesn’t mean you can just now, tomorrow, offer new services,” Saunders said.
While the April rule also increased MA payment rates by 2.5% in 2019 (and rates are expected to hike another 1.6% for 2020), payers also have only a finite amount of funds they can pay back toward medical care. Medicare reimburses MA plans a fixed amount each month, so to provide auxiliary benefits payers have to trim down in other areas.
“If you’re paying for groceries, what else is getting cut?” Jennifer Callahan, executive director of MA product strategy and implementation for Aetna, said. “Is groceries more important than dental coverage? We don’t know.”
Under the CMS regulatory guidance, MA organizations can only develop and offer non-traditional medical benefits if they have a reasonable expectation the services will boost health. That has injected a lot of confusion into the system for payers that may not know what that means, how to measure it and whether they’ll be penalized for slipping up.
“Health plans, especially the small ones, are still looking for clarification on what’s actually allowed,” Nick Johnson, principal at actuarial and consulting firm Milliman, said. Smaller payers often don’t have a large enough sample size to draw conclusions about the positives and negatives of offering specific supplemental benefits, especially in light of substandard quality measuresissued from CMS.
A subset of the expanded nonmedical benefits that address social determinants of health factors are officially called “Special Supplemental Benefits for the Chronically Ill” (SSBCI) and can only be offered to an “eligible chronically ill enrollee”: those who have at least one chronic condition and a high risk of hospitalization or adverse health outcomes and require coordinated care.
MA plans can currently offer nonmedical benefits to enrollees for a limited duration of time — typically four weeks, a CMS spokesperson told Healthcare Dive. But only under SSBCI can plans provide these benefits over the long term.
That pigeonholes MA plans from providing additional benefits for a wider spectrum of patients — for example, a person recuperating with serious injuries following a fall who can’t go out and get groceries themselves might appreciate getting them delivered.
However, “just because you were perfectly healthy before, you by definition don’t qualify,” Aetna’s Callahan said. “For me that’s one of the biggest gaps.”

More flexibility unlikely to help rural enrollees

Another concern is that the supplemental benefits could potentially exacerbate health disparities, including the divide between services offered in rural versus urban areas. Non-metropolitan markets tend to be highly concentrated, meaning just one or two insurers dominate the space.
MA is no different. In 619 U.S. counties that account for 4% of overall Medicare beneficiaries, no more than 10% of beneficiaries are enrolled in the privately-run Medicare plans, according to the Kaiser Family Foundation. Many of these low-penetration counties are in rural areas, and less competition means less reason to offer diversified, comprehensive coverage.
“At a national level, what we’re seeing is other places in the country where there’s at least one new benefit offered tend to be urban,” Saunders said.
Many of the add-on services require a specialty workforce — for example, at-home caregivers for long-term services and supports or drivers for non-emergency medical transportation. That makes it harder for plans to introduce them in rural areas that may already be suffering from workforce shortages, a lack of primary care physicians or health facilities, experts said.
For non-emergency medical transportation, companies like Uber and Lyft are combating lower use in rural areas with scheduled rides. Larger NEMT brokers will also partner with transportation companies in the community.
But offering supplemental benefits such as NEMT must be profitable for the insurer and its local partners, experts said. Initiatives that don’t yield a strong return on investment will likely be phased out for the next plan year.
“It’s a really difficult space to be in terms of scalability right now,” Callahan said. “It’s going to take some time.”

Telehealth use increasing most among non hospital-based providers

  • Providers not based in hospitals are rapidly adopting telehealth, reaching about 1% of all claims studied by nonprofit FAIR Health in a recent white paper. In 2018, non hospital-based providers accounted for 84% of all telehealth claims, up from 52% in 2014.
  • Those most likely to use telehealth services were people aged 31 to 40, accounting for 21% of claims. Women used telehealth more often than men, according to the report, which analyzed more than 29 billion private health claims records.
  • The conditions most associated with telehealth use were upper respiratory infection, mood disorders and anxiety or other nonpyschotic mental disorders, FAIR Health said.

Provider interest in telehealth is rising. The number of physicians reporting telemedicine as a skill has increased 20% over the past three years, according to Doximity. A recent report from the American Telemedicine Association found recognition of telehealth at the state level has gone up, with most states expanding coverage and reimbursement for it.
And patients are taking doctors up on the offerings. Another recent report from FAIR Health showed use of telehealth services is growing faster than usage at retail clinics, urgent care centers and emergency departments. The most recent FAIR Health findings show overall telehealth claims increasing 624% from 2014 to 2018.
One important draw for patients is the convenience of a virtual visit, especially for those with strict work schedules, who most likely fall in that age 31-40 cohort, FAIR Health President Robin Gelburd told Healthcare Dive.
“With increased coverage as a result of the Affordable Care Act, the question is whether access keeps pace with that increased insurance coverage,” she said. “I think what we’re seeing is the healthcare ecosystem conforming to an expanded insured population trying to access care in ways that are innovative and do offer a level of convenience.”
But while usage is increasing, several obstacles hinder broader adoption of telehealth. Reimbursement is lagging, providers face accrediting hurdles, and rural areas can struggle to get the high-speed internet access necessary to implement telehealth.
The Federal Communication Commissions is attempting to alleviate rural concerns through a pilot program that gives a discount on connectivity for broadband-enabled telehealth services directly connecting doctors and patients.
CMS is slowly opening more reimbursement avenues for telehealth services, particularly through expanded benefit options under Medicare Advantage. HHS Secretary Alex Azar said at an MA-focused conference this week his department wants to offer “more opportunities for MA plans and entities they work with, including creative value-based insurance design arrangements, moving care to the home and community and new ways for MA plans to improve a patients’ health over the long term.”
https://www.healthcaredive.com/news/telehealth-use-increasing-most-among-non-hospital-based-providers/559363/

Telehealth use increasing most among non hospital-based providers

  • Providers not based in hospitals are rapidly adopting telehealth, reaching about 1% of all claims studied by nonprofit FAIR Health in a recent white paper. In 2018, non hospital-based providers accounted for 84% of all telehealth claims, up from 52% in 2014.
  • Those most likely to use telehealth services were people aged 31 to 40, accounting for 21% of claims. Women used telehealth more often than men, according to the report, which analyzed more than 29 billion private health claims records.
  • The conditions most associated with telehealth use were upper respiratory infection, mood disorders and anxiety or other nonpyschotic mental disorders, FAIR Health said.

Provider interest in telehealth is rising. The number of physicians reporting telemedicine as a skill has increased 20% over the past three years, according to Doximity. A recent report from the American Telemedicine Association found recognition of telehealth at the state level has gone up, with most states expanding coverage and reimbursement for it.
And patients are taking doctors up on the offerings. Another recent report from FAIR Health showed use of telehealth services is growing faster than usage at retail clinics, urgent care centers and emergency departments. The most recent FAIR Health findings show overall telehealth claims increasing 624% from 2014 to 2018.
One important draw for patients is the convenience of a virtual visit, especially for those with strict work schedules, who most likely fall in that age 31-40 cohort, FAIR Health President Robin Gelburd told Healthcare Dive.
“With increased coverage as a result of the Affordable Care Act, the question is whether access keeps pace with that increased insurance coverage,” she said. “I think what we’re seeing is the healthcare ecosystem conforming to an expanded insured population trying to access care in ways that are innovative and do offer a level of convenience.”
But while usage is increasing, several obstacles hinder broader adoption of telehealth. Reimbursement is lagging, providers face accrediting hurdles, and rural areas can struggle to get the high-speed internet access necessary to implement telehealth.
The Federal Communication Commissions is attempting to alleviate rural concerns through a pilot program that gives a discount on connectivity for broadband-enabled telehealth services directly connecting doctors and patients.
CMS is slowly opening more reimbursement avenues for telehealth services, particularly through expanded benefit options under Medicare Advantage. HHS Secretary Alex Azar said at an MA-focused conference this week his department wants to offer “more opportunities for MA plans and entities they work with, including creative value-based insurance design arrangements, moving care to the home and community and new ways for MA plans to improve a patients’ health over the long term.”

Pharmacquired: Neuroscience M&A is top of mind but a hard pill to swallow

Investors had a feeling about Loxo Oncology. Of the 74 responding to a December survey from RBC Capital Markets, more than a fifth said the cancer drug company could see takeover interest in 2019. Just a few weeks later, Eli Lilly affirmed their suspicions with an $8 billion buyout.
Loxo wasn’t investors’ top takeover target, however. It ranked third, trailing biotechs Sarepta Therapeutics and Sage Therapeutics. In the fourth slot was another company working on neuroscience-related medicines, Neurocrine Biosciences.
Fast forward eight months, and Sarepta, Sage and Neurocrine remain independent. That’s likely to continue, both for them and similar companies. Because in spite of scientific breakthroughs and shareholder optimism, there is still skepticism that neuroscience drugs either won’t make it to market or will be too expensive to acquire if they do.
“A lot of stars need to align for business development to actually occur,” said Sumant Kulkarni, an analyst at Canaccord Genuity, in an interview with BioPharma Dive.
Perhaps the most obvious of those is a viable buyer. Typically, that means a mid- to large-cap company with billions of dollars at its disposal — a suitor that has become rarer in the neurosciences.
Pfizer, Bristol-Myers Squibb, GlaxoSmithKline and AstraZeneca all exited the space over the past decade, while fellow heavyweights like Lilly, Sanofi and Merck & Co. narrowed their focus and investments.
For companies that stayed, M&A hasn’t been as attractive as it has with cancer drugs or, lately, cell and gene therapy. There have been 12 neuroscience acquisitions valued at $1 billion or more since 2009, according to Pitchbook, whereas oncology saw at least four deals of that size since December alone.
Top M&A for companies working in neuroscience
ACQUIRERTARGETDEAL VALUECLOSING
PfizerWyeth$68 billionJan. 2009
TakedaShire$62.4 billionJan. 2019
NovartisAveXis$8.7 billionMay 2018
PerrigoElan$8.6 billionJuly 2013
Otsuka PharmaceuticalAvanir Pharmaceuticals$3.5 billionJan. 2015
AllerganNaurex$1.7 billionAug. 2015
MallinckrodtCadence Pharmaceutcials$1.4 billionMarch 2014
MerckAfferent Pharmaceuticals$1.3 billionJuly 2016
Forest LaboratoriesClinical Data$1.2 billionApril 2011
LundbeckPrexton Therapeutics$1.1 billionMarch 2018
Mitsubishi Tanabe PharmaNeuroDerm$1.1 billionOct. 2017
AllerganChase Pharmaceuticals$1 billionNov. 2016
Eli LillyCoLucid Pharmaceuticals$960 millionMarch 2017
Allergan (pre-Actavis)Map Pharmaceuticals$958 millionJan. 2013
Otsuka PharmaceuticalAstex Pharmaceuticals$886 millionOct. 2013
BiogenConvergence Pharmaceuticals$657 millionFeb. 2015
PfizerBamboo Therapeutics$645 millionAug. 2016
RocheTrophos$509 millionMarch 2015
BiogenPanima Pharmaceuticals$428 millionDec. 2010
LundbeckAbide Therapeutics$400 millionMay 2019
Acorda TherapeuticsBiotie Therapies$376 millionApril 2016
Show more
SOURCE: Pitchbook
The largest deals involving neuroscience drugs were also just as much about other therapeutic areas: Pfizer got the blockbuster Prevnar vaccine from Wyeth; Takeda gained a portfolio of rare disease treatments and a global footprint through Shire; and Novartis, according to AveXis, highlighted its commitment to gene therapy, not neuroscience, when courting the biotech.
But Stifel analyst Paul Matteis argues neuroscience M&A isn’t necessarily tied to the depth of the buyer pool.
Rather, one reason for its scarcity has been the vast amount of money neuroscience biotechs are collecting from venture funds and public markets, which makes them less dependent on deals with big pharma.
report from BIO, the biotech industry trade group, found neurology companies received $1.45 billion in venture capital last year, putting them second only to oncology drugmakers.
That’s not a new trend either. Across 14 therapeutic areas followed by BIO, neurology consistently placed in the top five for venture capital funding over the past 10 years.
“Investors have shown a real willingness to give companies the capital to find out if some of these earlier-stage products that seem theoretically promising are real drugs,” Matteis said in an interview with BioPharma Dive.
The track record for finding these “real” neuroscience drugs isn’t great, however, due in no small part to the complicated biology of the brain. Alzheimer’s disease illustrates the challenges, as it continues to stump powerful pharmaceutical giants like AstraZeneca, Biogen, Merck and Roche.
“You can imagine, if you’re an analyst or a stockholder and you saw a company in your portfolio buy a late-stage Alzheimer asset, you’d be really scared and may punish that company for doing it,” Jeffrey Quillen, a partner at law firm Foley Hoag, told BioPharma Dive.
SOURCE: Pitchbook
Setbacks are common in other neurological conditions too. The last year and a half saw misfires from Intra-Cellular in bipolar depression; Allergan in depression; Aptinyx in painful diabetic peripheral neuropathy; Acadia Pharmaceuticals in schizophrenia; and Astellas and Cytokinetics in ALS.
Additionally, Alkermes announced in February that the Food and Drug Administration had rejected its experimental depression drug.
“Neuroscience is very tough to run clinical trials in,” Kulkarni said. “Subjective endpoints and things like that make it very difficult to get good signals to show you whether a drug actually works.”
Still, a handful of companies in recent years have been able to clear the clinical and regulatory hurdles
Sage received in March the first ever FDA nod for a post-partum depression treatment. The Massachusetts biotech is testing a follow-on drug, SAGE-217, for a broader range of depression disorders.
Sarepta holds an approved product as well in Exondys 51 for Duchenne muscular dystrophy, or DMD, but its impact on patients is questionable. Regulators are currently reviewing its second DMD drug, and a gene therapy also aimed at the condition has drawn considerable attention.
Neurocrine actually brought two new treatments to market. It created Orilissa for endometriosis pain, with help from AbbVie, and discovered Ingrezza for tardive dyskinesia, a side effect of antipsychotic medications characterized by sudden, involuntary movements.
These successes are what paint Sarepta, Sage and Neurocrine as attractive biotechs primed for an acquisition. Yet they also make any buyout a pricer proposition.

Mylan’s tumble ends with Pfizer rescue

Pfizer’s on-again, off-again breakup is back on again. Off-patent branded drugs like Lipitor, Lyrica and Viagra will now be in the hands of a new company formed from a merger of the big pharma’s Upjohn unit with struggling generics manufacturer Mylan.
The transaction addresses immediate problems for both companies, with Mylan picking up sizable Upjohn cash flow to offset its own sliding sales and ease debt pressures. For its part, Pfizer offloads a division that was diluting its own growth prospects in branded pharmaceuticals.
But while executives from both companies described the deal as “transformational,” the long-term promise is anything but certain as generics remain under pricing pressure in developed markets and Upjohn’s business in emerging markets remains volatile.
The deal partially answers a question that has vexed Pfizer investors for some time — namely, would the biggest big pharma split itself up to achieve a higher overall valuation than the conglomerate now offers? Former CEO Ian Read posed the question nearly a decade ago before deciding against it, but a recent decision to have business units report financial data separately raised it as possibility again.
For the sector at large, as Pfizer goes, so go other pharma companies. Ridding themselves of sluggish generics business units might also benefit a company like Novartis, which sells off-patent drugs under the Sandoz name.
Meanwhile, the decision to merge with Upjohn brings to an end a strategic review that Mylan began nearly a year ago.
The transaction will launch a boardroom shuffle as Pfizer shareholders will take a 57% stake in the new company. As a result, Mylan CEO Heather Bresch will step down following the deal’s close and be replaced by Upjohn’s group president, Michael Goettler. Mylan chairman Robert Coury will become executive chairman.
Joining Coury and Goettler on the board of directors will be eight members designated by Mylan and three by Pfizer.
The deal will also see Mylan’s legal domicile return to the U.S. following an “inversion” that took place in 2014 when it bought the Netherlands-headquartered generics division of Abbott Laboratories, at a time when such transactions were under serious scrutiny from U.S. regulators concerned of their use to escape tax obligations.
Mylan has been one of the hardest hit companies by generic pricing pressures, with its revenues declining 4% year over year from 2017 to 2018, to $11.4 billion. North American revenue, which constituted 35% of its sales, dropped even more severely, by 18%.
Upjohn, meanwhile, is a more globally diversified company, with 55% of its sales in the Asia-Pacific region and 15% in emerging markets. The new company will have 30% in Asia-Pacific and 15% in emerging markets.
The advantages of that global presence are potentially offset by the structure of Upjohn, however. As an operating unit within Pfizer, its sales outlook can be replenished by branded products that go off-patent but have a significant tail of revenue. This will not be something the new company can rely on.
Two-thirds of Upjohn’s sales come from its top three products, Lyrica, Lipitor and Norvasc, which will be ripe targets for generic rivals.
“In other words, sales will shrink over time,” Raymond James analyst Elliot Wilbur wrote in a note to clients. “[Mylan] is giving up 60% of everything management has built over 60 years for what in essence appears to be a medium duration rescue package.”
It does give Mylan investors something to love, however. Executives promised to bring Mylan’s debt, which stood at more than $13 billion at the end of 2018, down to two and a half times earnings, and begin paying a dividend of 25% of free cash flow, estimated at more than $4 billion, in the first quarter after the deal’s close.
Those goals will be helped along by an estimated $1 billion in annual cost savings the executives targeted by 2024.
The deal is expected to close mid-2020, subject to vote by Mylan shareholders and regulatory review.

UnitedHealth grows in market questioned by critics

With the recent acquisition of a Texas-based company, UnitedHealth Group has waded deeper into the sale of “supplemental” health plans that consumer advocates say provide questionable value to subscribers.
Earlier this year, Minnetonka-based UnitedHealth Group acquired a company called HealthMarkets Inc., which includes a division for supplemental insurance policies that last year covered about 850,000 people.
For several years, UnitedHealth has been selling some forms of the coverage, which in many cases provide a lump sum of money in the event of certain health care problems such as cancer, hospitalization or a critical illness. Sometimes called “dread disease” policies, the coverage is becoming more of a target for consumer advocates as more insurers try to grow the market.
“It is very much ‘buyer beware’ when it comes to these products,” said Sabrina Corlette, a researcher with the Center on Health Insurance Reforms at Georgetown University. The concern is that supplemental policies pay out a relatively low share of the premium dollar in benefits, Corlette said, adding that consumers who rely on the policies as an alternative to comprehensive coverage are making a risky bet.
UnitedHealth Group argues the policies are a low-premium option that works well for some consumers as an adjunct to comprehensive health insurance. These policies have become more important, the company says, as more consumers have high-deductible health plans that require significant out-of-pocket spending when people need care.
The coverage typically provides cash directly to consumers, rather than payments to doctors and hospitals for medical services. The company cites federal data showing the average cost of a hospital stay including ambulance transport exceeds $11,000, adding that nearly two-thirds of the workforce has less than $1,000 on hand to pay out-of-pocket expenses for an unexpected serious illness or emergency.
Matt Wiggin, a UnitedHealth Group spokesman, said the largest part of the business at HealthMarkets Inc. is an insurance agency that sells comprehensive insurance coverage in almost all 50 states, not just supplementary plans. Overall, HealthMarkets employs about 550 people.
“A significant portion of HealthMarkets’ business is driven by their portfolio of supplemental insurance products, which are offered in 46 states and the District of Columbia,” UnitedHealth Group said in a statement. “These offerings help strengthen UnitedHealthcare’s portfolio of critical illness, accident, fixed indemnity and other supplemental products.”
UnitedHealth Group is Minnesota’s largest company in terms of revenue. The company’s UnitedHealthcare division, which is the nation’s largest health insurer, disclosed the HealthMarkets acquisition in May in a regulatory filing.
The acquired company’s division for supplementary coverage, which is called Chesapeake Life Insurance, disclosed the acquisition in an earlier filing, saying the merger with a UnitedHealth Group affiliate called Golden Rule Financial Corp. was finalized on Feb. 1.
Financial terms were not released. In 2018, Chesapeake Life Insurance posted $222.4 million in revenue.
“We’re trying to build a diverse suite of product options for the individual market, affordable options for it,” said David Wichmann, the UnitedHealth Group chief executive, when asked about the acquisition during an investor conference in May.
Last year, Jackson Williams, the general counsel of a consumer group called Dialysis Patient Citizens, presented data to the National Association of Insurance Commissioners (NAIC) showing an industrywide decline in “loss ratios” for various lines of supplemental coverage.
A loss ratio shows the share of the premium dollar that’s paid out in benefits, and Williams’ report asserted that when the ratio falls below 50% it “indicates that paying claims is not the principal function of the product but rather an incidental function.” He compiled data showing that between 2009 and 2017, loss ratios fell below 50% for at least four different types of supplemental policies including “other medical” policies sold to individuals and “specified disease” policies sold to consumers via employer groups.
“If [a benefit counselor] can sell you a dread-disease policy or a hospitalization-only policy or one of these other schlock policies, they can make a lot of money,” said Williams, who is a consumer liaison representative to NAIC. “What we’re asking for is that the loss ratio for these products be disclosed at the point of sale.”
Without citing products from particular companies, he added: “These limited-benefit plans I would call opportunistic. You’re appealing to somebody’s desire for peace of mind, but it’s not really a product that adds value. … It’s a very overpriced product.”
But America’s Health Insurance Plans, a trade group for carriers, defended the products. Loss ratios on the products can be particularly low at the beginning of coverage, the trade group says, since premiums tend to hold steady year-to-year while benefit claims increase over time.
The federal Affordable Care Act requires that individual and group policies have loss ratios of at least 80% and requires consumer rebates when insurers pay out a lesser share on health care. But the health law excluded supplemental policies from those rules, because they are “intended to supplement, not substitute for, major medical coverage,” the trade group said in a statement.
“Despite having lower premiums, the amount of work needed to administer these products can be similar to comprehensive coverage,” the trade group said. “As such, a larger portion of the premium dollar will go to administrative costs.”
Williams said he was skeptical of that argument.
“Many of these are ‘lump sum’ policies that do not review medical expenditures to quantify the claim, only the diagnosis,” he said via e-mail. “A health insurer needs to have a medical director, utilization review, credentialing, quality improvement, coding, pay for performance programs, etc., and deals with Medicare Advantage and Medicaid managed care complexities, too.”
Supplemental insurance policies are a small part of the overall business at UnitedHealth Group, which primarily sells comprehensive coverage, said Wiggin, the company spokesman. A key reason for the HealthMarkets acquisition, he added, was independent of the supplemental insurance business.
The acquired company’s insurance agency and “distribution” business includes “career agents, call centers, direct-to-consumer, and brokerage channels,” Wiggin wrote in an e-mail. The company has more than 200 offices and retail locations, Wiggin said, and works with 3,000 agents.
“Consumers are continuing to look for ways to meet their various health and other insurance needs,” UnitedHealth Group said in a statement. The purchase fits with the company’s goal to “reach even more people, quickly and efficiently, and in the way they prefer to be reached.”

J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Shares of the company traded marginally down at $132.47, after having closed up 1.7% on Monday.
J&J said that the FTC had issued a “civil investigative demand,” or CID, the equivalent of a subpoena to determine if the contracting practices were legal.
Pfizer Inc filed a lawsuit against J&J in 2017, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and aimed at blocking sales of Pfizer’s biosimilar called Inflectra.
Pfizer said in the lawsuit that J&J had contracted with many insurers to give discounts in exchange for giving preference to Remicade, and to only pay for Inflectra in cases where Remicade proved to be ineffective. Inflectra was approved in 2016 while Remicade went on the market in 1998.
Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the lawsuit.
J&J has denied any wrongdoing and is fighting the Pfizer lawsuit.
Pfizer said in a statement that it had received a CID in June.
“As Pfizer’s complaint alleges, J&J’s unlawful conduct is designed to prevent Inflectra from being able to compete on its primary point of differentiation – price. Today, Inflectra has an average selling price (ASP) that is more than 22% lower than Remicade,” the company said in a statement. “Despite these facts, J&J has not lost substantial volume or share of sales – counter to what should occur in a competitive market.”
Biosimilars are intended to be lower-cost alternatives to expensive biotech medicines. But since they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be.
The drugs treat ailments like rheumatoid arthritis, Crohn’s disease and ulcerative colitis.